Lundbeck fine: industry outraged over messy patent system
This article was originally published in Scrip
Executive Summary
Lundbeck has branded as "erroneous" the European Commission's decision to fine it for anticompetitive behavior, while the European industry federation , EFPIA, has claimed that the affair flags up deficiencies in the European patent litigation system and raises cause for concern with implications for innovation, patient welfare and economic growth.
You may also be interested in...
EU Pay-For-Delay Ruling Against Lundbeck Sends Signal To Others, Including UK Competition Body
The EU’s General Court has upheld the European Commission’s decision to fine Lundbeck and a number of generics firms for agreeing to keep generic versions of the antidepressant citalopram off the market in return for payments. The ruling could have implications for other similar cases such as that involving GlaxoSmithKline’s paroxetine in the UK.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.